Sep, 30 2019 12:06 JST

Source: Eisai

Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China


TOKYO, Sep, 30 2019 - (JCN Newswire) - Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.

The Chinese pharmaceutical market is the second largest market in the world after the United States, and the generic drugs account for more than 70% of its market in terms of value. Also, due to the rapid aging and the government's policies to promote the generic drug market, the continuous growth of generic drugs is predicted. Furthermore, in order to improve the quality of generic drugs, the Chinese government is establishing the stable supply system of high quality generic drugs equivalent to the original drugs, such as it introduces the generic quality consistency evaluation system and provides priority response to the government's centralized procurement system for the generic drugs which have passed its evaluation test.

Under this agreement, Eisai and Nichi-Iko aim to enhance their pharmaceutical businesses in China by introducing the high quality generic drugs which Nichi-Iko maintains the marketing approval in Japan. Eisai and Nichi-Iko specifically select the appropriate products for the Chinese market needs, and Eisai's subsidiary in China sells the products after Nichi-Iko obtains the approval for import and sales in China. Eisai and Nichi-Iko will select the first two products in this fiscal year, and subsequently prepare to launch one to two products every year for the continuous launch from FY2024.

Due to this agreement, Eisai will address a broader range of medical needs in China by further strengthening its Chinese generic business since entering in 2015. Nichi-Iko aims to enter the Chinese market leveraging the Eisai's business foundation in China, as part of the strategic imperatives, "Business Expansion" and "Global Operation" in the 8th Medium-term Management Plan "NEXUS∞".

In March 2018, Eisai and Nichi-Iko has entered into a strategic alliance agreement for the generic pharmaceutical business in Japan. By developing the partnership between Eisai and Nichi-Iko in China, Eisai and Nichi-Iko will aim to expand the contribution to patients in China as well as attempt to expand and grow their businesses in China.

The impact of the agreement has no impact on the financial results for fiscal 2019 for either company.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.


Contact:
Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120
FAX: +81-(0)3-3811-3077
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
October 23 2019 10:13 JST
 
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
October 15 2019 20:24 JST
 
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
October 01 2019 10:46 JST
 
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
September 26 2019 13:21 JST
 
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
September 26 2019 13:08 JST
 
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress
September 24 2019 09:01 JST
 
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
September 20 2019 15:13 JST
 
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India
September 20 2019 08:40 JST
 
Eisai to Present Latest Data on Lemborexant at World Sleep Congress
September 19 2019 19:06 JST
 
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019
September 18 2019 20:40 JST
 
More Press release >>

Latest Press Release


More Latest Release >>